588 related articles for article (PubMed ID: 26703797)
21. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
Zhang S; Yan B; Zheng J; Zhao J; Zhou J
Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
[TBL] [Abstract][Full Text] [Related]
22. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T
Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adoloscents and young adults.
Scarpino S; Rampioni Vinciguerra GL; Di Napoli A; Fochetti F; Uccini S; Iacono D; Marchetti P; Ruco L
Lung Cancer; 2016 Jul; 97():95-8. PubMed ID: 27237034
[TBL] [Abstract][Full Text] [Related]
24. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
Lee SE; Lee B; Hong M; Song JY; Jung K; Lira ME; Mao M; Han J; Kim J; Choi YL
Mod Pathol; 2015 Apr; 28(4):468-79. PubMed ID: 25234288
[TBL] [Abstract][Full Text] [Related]
26. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
[TBL] [Abstract][Full Text] [Related]
28. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
[TBL] [Abstract][Full Text] [Related]
29. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
[TBL] [Abstract][Full Text] [Related]
30. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
32. RET, ROS1 and ALK fusions in lung cancer.
Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
[TBL] [Abstract][Full Text] [Related]
33. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.
Tang Z; Zhang J; Lu X; Wang W; Chen H; Robinson MK; Cheng J; Tang G; Medeiros LJ
Mod Pathol; 2018 Feb; 31(2):307-312. PubMed ID: 28914263
[TBL] [Abstract][Full Text] [Related]
34. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
J Mol Diagn; 2018 Mar; 20(2):129-159. PubMed ID: 29398453
[TBL] [Abstract][Full Text] [Related]
35. [Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma].
Fournier C; Greillier L; Fina F; Secq V; Nanni-Metellus I; Loundou A; Garcia S; Ouafik L; Tomasini P; Barlesi F
Rev Mal Respir; 2016 Nov; 33(9):751-756. PubMed ID: 27017063
[TBL] [Abstract][Full Text] [Related]
36. [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
López-Ríos F; Paz-Ares L; Sanz J; Isla D; Pijuan L; Felip E; Gómez-Román JJ; de Castro J; Conde E; Garrido P
Rev Esp Patol; 2020; 53(3):167-181. PubMed ID: 32650968
[TBL] [Abstract][Full Text] [Related]
37. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
38. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.
Vaughn CP; Costa JL; Feilotter HE; Petraroli R; Bagai V; Rachiglio AM; Marino FZ; Tops B; Kurth HM; Sakai K; Mafficini A; Bastien RRL; Reiman A; Le Corre D; Boag A; Crocker S; Bihl M; Hirschmann A; Scarpa A; Machado JC; Blons H; Sheils O; Bramlett K; Ligtenberg MJL; Cree IA; Normanno N; Nishio K; Laurent-Puig P
BMC Cancer; 2018 Aug; 18(1):828. PubMed ID: 30115026
[TBL] [Abstract][Full Text] [Related]
40. An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology.
Piton N; Lanic MD; Marguet F; Lamy A; Blanchard F; Guisier F; Viennot M; Salaün M; Thiberville L; Jardin F; Sabourin JC; Ruminy P
Lab Invest; 2021 May; 101(5):648-660. PubMed ID: 33495574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
